In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

VEGF-A gene polymorphism and VEGF-A level association with the development of heart failure in patients with ST-elevation myocardial infarction

Session Poster Session 3

Speaker Iulia Rodionova

Event : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session

Authors : I Rodionova (Kharkiv,UA), I N Kutya (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), YJ Samburg (Kharkiv,UA), NV Tytarenko (Kharkiv,UA), BA Shelest (Kharkiv,UA)

I Rodionova1 , I N Kutya1 , MP Kopytsya1 , YJ Samburg2 , NV Tytarenko1 , BA Shelest3 , 1L.T.Malaya Institute of Therapy - Kharkiv - Ukraine , 2Kharkiv National Academy of Postgraduate Education - Kharkiv - Ukraine , 3Kharkiv National Medical University - Kharkiv - Ukraine ,


The purpose of the study was to assess the predictive value of Vascular endothelial growth factor A (VEGF-A) in associated with in cardiac remodeling and  exercise capacity of the VEGF-A gene polymorphism (rs 2010963) with the development of heart failure in patients with ST-Elevation Myocardial Infarction (STEMI) in a 6-month period.

Materials and methods: 91 patients with acute STEMI were examined, 70 (76.9%) males, mean age - 59.21 ± 8.92. The level of the VEGF-A  determined by ELISA. VEGF-A gene polymorphism (rs 2010963)  assessed by polymerase chain reaction. All patients  tested with a 6-minute walking test (6MWT).

Results. Carriers of the genotype GG have a significantly higher level of VEGF-A - 194.10 [115.02-398.86] pg / ml compared to the GC genotype with 148.44 [68.84-221.28] pg / ml, (P = 0.047). The frequency of STEMI was 2.58 times higher in the GC genotype. The 6MWT was 477.35 ± 73.34 m in the GC type, meanwhile, the GG genotype resulted in 545.44 ± 51.09 m (P = 0.014). The ROC analysis determined the cut-off level of VEGF-A = 199.5 pg / ml, as a predictor for left ventricle (LV) remodelling and for poor exercise capacity with a sensitivity of 77.4% and a specificity of 63.3% (AUC 0.654, 95% CI 0.513-0.795, p = 0.032).

Conclusions: The GC genotype in patients with STEMI is associated with more pronounced changes in the LV geometry and poor exercise capacity. The VEGF-A can be suggested as possible predictor for heart failure development in STEMI patients.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are